Table 2.
Clinicopathologic characteristics of patients by PD-L1 expression
| Clinicopathologic parameters | PD-L1 in TC | P-value | PD-L1 in IC | P-value | ||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |||
| age | 0.01 | 0.06 | ||||
| ≤ 50 | 12(30.0%) | 28(70%) | 9(22.5%) | 31(77.5%) | ||
| >50 | 11(11.0%) | 89(89%) | 10(10.0%) | 90(90.0%) | ||
| tumor size | 0.221 | 0.101 | ||||
| ≤ 2.0 cm | 11 (13.3%) | 72 (86.7%) | 8(9.6%) | 75 (90.4%) | ||
| > 2.0 cm | 12 (21.1%) | 45 (78.9%) | 11 (19.3%) | 46 (80.7%) | ||
| Menopausal status | 0.011 | 0.001 | ||||
| postmenopausal | 10 (10.8%) | 83 (89.2%) | 9 (9.7%) | 84(90.3%) | ||
| menstruating | 13 (27.7%) | 34 (72.3%) | 10(21.3%) | 37(78.7%) | ||
| Histological subtype | 0.138 | 0.459 | ||||
| IDC | 21(18.8%) | 91(81.2%) | 14(13.0%) | 98(87.0%) | ||
| ILC | 2(7.1%) | 26(92.9%) | 5(17.9%) | 23(82.1%) | ||
| Histological classification of IDC | 0.117 | 0.001 | ||||
| I | 3 (10.3%) | 26 (89.7%) | 0(0.0%) | 29(100.0%) | ||
| II | 6 (17.1%) | 29 (82.9%) | 4(11.4%) | 31(88.6%) | ||
| III | 12 (25.0%) | 36(75.0%) | 10(20.8%) | 38(79.2%) | ||
| Nodal metastasis | < 0.01 | 0.066 | ||||
| Present | 19(30.6%) | 43(69.4%) | 12(19.4%) | 50(80.6%) | ||
| Absent | 4(5.1%) | 74(94.9%) | 7(9.0%) | 71(91.0%) | ||
| Lymphovascular Invasion | < 0.01 | < 0.01 | ||||
| Present | 18(41.9%) | 25(58.1%) | 14 (32.6%) | 29 (67.4%) | ||
| Absent | 5(5.1%) | 92(94.9%) | 5 (5.1%) | 92 (94.9%) | ||
| Ki-67 Index | 0.064 | 0.076 | ||||
| <14% | 9(27.2%) | 24(72.3%) | 8(24.2%) | 25(75.8) | ||
| >14% | 14(13.1%) | 93 (86.9%) | 11(10.3%) | 96(89.7%) | ||
| TNM Clinical Stage | < 0.01 | < 0.01 | ||||
| I ~ II | 7 (7.1%) | 91 (92.9%) | 6(6.1%) | 92(93.9%) | ||
| III ~ IV | 16 (38.1%) | 26 (61.9%) | 13(31.0%) | 29(69.0%) | ||
| ER | 0.001 | < 0.01 | ||||
| Positive | 6(7.3%) | 76(92.7%) | 2(2.4%) | 80(97.6) | ||
| Negative | 17(29.3%) | 41(70.7%) | 17(29.3%) | 41(70.7%) | ||
| PR | 0.104 | 0.007 | ||||
| Positive | 2(6.1%) | 31(93.9%) | 0(0%) | 33(100%) | ||
| Negative | 21(19.6%) | 86(80.4%) | 19(17.8%) | 88(82.2%) | ||
| HER-2 | 0.596 | 0.004 | ||||
| Positive | 6(16.2%) | 31(83.8%) | 5(13.5%) | 32(86.5%) | ||
| Negative | 17(16.5%) | 86(83.5%) | 14(13.6%) | 89(86.4%) | ||